Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.88 | N/A | -6.80% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.88 | N/A | -6.80% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current financial performance while reaffirming their commitment to long-term growth. They acknowledged the difficulties faced in the market.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in research and development.
There was a focus on long-term goals despite short-term setbacks.
The earnings report indicates that IDEAYA Biosciences is still facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 3.52%, likely due to investor concerns about the company's path to profitability and lack of revenue updates. Without clear guidance, uncertainty remains regarding future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 4, 2025